Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;34(6):e70005.
doi: 10.1002/rmv.70005.

Targeting the Ubiquitin Proteasome System to Combat Influenza A Virus: Hijacking the Cleanup Crew

Vandana Anang  1 , Laura Antonescu  1 , Richard Nho  1 , Sourabh Soni  1 , Yohannes A Mebratu  1
Affiliations
Review

Targeting the Ubiquitin Proteasome System to Combat Influenza A Virus: Hijacking the Cleanup Crew

Vandana Anang et al. Rev Med Virol. 2024 Nov.

Abstract

Influenza A virus (IAV) remains a significant global public health threat, causing substantial illness and economic burden. Despite existing antiviral drugs, the emergence of resistant strains necessitates alternative therapeutic strategies. This review explores the complex interplay between the ubiquitin proteasome system (UPS) and IAV pathogenesis. We discuss how IAV manipulates the UPS to promote its lifecycle, while also highlighting how host cells utilise the UPS to counteract viral infection. Recent research on deubiquitinases as potential regulators of IAV infection is also addressed. By elucidating the multifaceted role of the UPS in IAV pathogenesis, this review aims to identify potential targets for novel therapeutic interventions.

Keywords: E3 ligase; deubiquitinase; influenza A virus; ubiquitin proteasome system.

PubMed Disclaimer

References

    1. T. Lampejo, “Influenza and Antiviral Resistance: An Overview,” European Journal of Clinical Microbiology & Infectious Diseases 39, no. 7 (2020): 1201–1208, https://doi.org/10.1007/s10096‐020‐03840‐9.
    1. (CDC) CfDCaP. 2024. Health Equity and Flu, https://www.cdc.gov/flu/highrisk/disparities‐racial‐ethnic‐minority‐grou.... Accessed, September 16, 2024.
    1. F. G. Hayden, “Perspectives on Antiviral Use During Pandemic Influenza,” Philosophical Transactions of the Royal Society of London B Biological Sciences 356, no. 1416 (2001): 1877–1884, https://doi.org/10.1098/rstb.2001.1007.
    1. W. L. Davies, R. R. Grunert, R. F. Haff, et al. “Antiviral Activity of 1‐Adamantanamine (Amantadine),” Science 144, no. 3620 (1964): 862–863, https://doi.org/10.1126/science.144.3620.862.
    1. R. A. Bright, M. J. Medina, X. Xu, et al. “Incidence of Adamantane Resistance Among Influenza A (H3N2) Viruses Isolated Worldwide from 1994 to 2005: A Cause for Concern,” Lancet 366, no. 9492 (2005): 1175–1181, https://doi.org/10.1016/s0140‐6736(05)67338‐2.

MeSH terms

LinkOut - more resources